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O B J E C T I V E S The goal of this study was to determine the ability of a single, resting high-sensitivity
troponin T (hsTnT) measurement to predict abnormal myocardial perfusion imaging (MPI) in patients
presenting with acute chest pain to the emergency department (ED).
B A C KG ROUND HsTnT assays precisely detect very low levels of troponin T, which may be a
surrogate for the presence and extent of myocardial ischemia.
METHOD S We included all patients from the ROMICAT I (Rule Out Myocardial Infarction Using
Computer Assisted Tomography) trial, an observational cohort study, who underwent both single-
photon emission computed tomography (SPECT)-MPI stress testing and 64-slice computed tomography
angiography (CTA) and in whom hsTnT measurements were available. We assessed the discriminatory
value of hsTnT for abnormal SPECT-MPI and the association of reversible myocardial ischemia by
SPECT-MPI and the extent of coronary atherosclerosis by CTA to hsTnT levels.
R E S U L T S Of the 138 patients (mean age 54 11 years, 46%male), 19 (13.7%) had abnormal SPECT-MPI.
Median hsTnT levels were signiﬁcantly different between patients with normal and abnormal SPECT-MPI (9.41
pg/ml [interquartile range (IQR): 5.73 to 19.20 pg/ml] vs. 4.89 pg/ml [IQR: 2.34 to 7.68 pg/ml], p  0.001).
Sensitivity of 80% and 90% to detect abnormal SPECT-MPI was reached at hsTnT levels as low as 5.73 and
4.26 pg/ml, respectively. Corresponding speciﬁcity was 62% and 46%, and negative predictive value was 96%
and 96%, respectively. HsTnT levels had good discriminatory ability for prediction of abnormal SPECT-MPI
(area under the curve: 0.739, 95% conﬁdence interval: 0.609 to 0.868). Both reversible myocardial ischemia
and the extent of coronary atherosclerosis (combined model r2 0.19 with partial of r2 0.12 and r2 0.05,
respectively) independently and incrementally predicted the measured hsTnT levels.
CONC L U S I O N S In patients with acute chest pain, myocardial perfusion abnormalities and
coronary artery disease are predicted by resting hsTnT levels. Prospective evaluations are warranted to
conﬁrm whether resting hsTnT could serve as a powerful triage tool in chest pain patients in the ED
before diagnostic testing and improve the effectiveness of patient management. (J Am Coll Cardiol
Img 2013;6:72–82) © 2013 by the American College of Cardiology Foundation
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73T
raditionally, cardiac troponin T (TnT) has
been considered a specific marker for myocar-
dial necrosis and thus represents a diagnostic
hallmark for the diagnosis of acute myocardial
nfarction as well as a predictor of major adverse
ardiac events (1,2). Although conventional TnT
ssays were unreliable for the detection of troponin
0.01 ng/ml, a novel, so-called “high-sensitivity”
ssay demonstrates greatly improved precision and
hus permits the reliable detection of much lower
oncentrations of TnT with great precision (99th
See page 83
percentile of hsTnT for a normal reference popu-
lation: 13 pg/ml, imprecision 10%) (3–6). Hith-
erto, the new assays detect measurable amounts of
TnT at lower levels than those pre-specified for
myocardial necrosis, even in patients without symp-
toms of cardiovascular disease, and predict cardio-
vascular morbidity and mortality in patients with
and without overt coronary artery disease (CAD)
(7–10). In addition, Sabatine et al. (11) recently
demonstrated a stress-induced rise in cardiac tro-
ponin I levels as measured with a high-sensitivity
assay that correlated with reversible myocardial
ischemia as demonstrated by single-photon emis-
sion computed tomography–myocardial perfusion
imaging (SPECT-MPI). These observations led to
the intriguing hypothesis that these new assays may
permit tracking of CAD development over time
and also permit the detection of acute myocardial
ischemia. This hypothesis has been supported by
our previous results demonstrating that hsTnT
assays permit improved detection of acute coronary
syndromes (ACS) as compared with conventional
TnT among patients presenting with acute chest
pain to the emergency department (ED), because
patients later classified as having unstable angina are
identified sooner using hsTnT (12). In addition,
this study demonstrated a close association of
hsTnT with cardiac structure and function as de-
termined by computed tomography (CT).
To further determine the potential role of
hsTnT to risk stratify patients presenting with
‡Division of Cardiology, Massachusetts General Hospital, Harvard
§Department of Cardiology, University of Ulm, Ulm, Germany. This wor
reagents for high-sensitivity troponin assays were provided free by Roche D
received support from NIH grant T32HL076136. Dr. Truong also rece
L30HL093896. Dr. Januzzi has received grant support from Roche Dia
other authors have reported that they have no relationships relevant to thManuscript received January 4, 2012; revised manuscript received August 17acute chest pain to the ED, but without objective
evidence of ACS on admission, we assessed the
discriminatory power of resting hsTnT levels to
predict abnormal rest and stress SPECT-MPI. In
addition, we assessed whether both myocardial
ischemia and coronary atherosclerosis indepen-
dently predict hsTnT, which would establish
hsTnT as a surrogate marker for myocardial
injury both in patients with nonobstructive or
obstructive CAD.
M E T H O D S
Patient population. Details of the
OMICAT (Rule Out Myocardial Infarc-
ion Using Computer Assisted Tomogra-
hy) study have been previously reported
13). Briefly, ROMICAT was a double-
linded, single-center, prospective obser-
ational cohort study of consecutive adult
atients at low-to-intermediate likelihood
f ACS presenting to the ED of Massa-
husetts General Hospital with acute chest
ain, and whose initial electrocardiogram
ECG) and biomarkers were not indica-
ive of a high likelihood for ACS. The
nrollment period was a cumulative period
f 18 months ending May 2007. Exclusion
riteria were atrial fibrillation, serum cre-
tinine 1.3 mg/dl, and personal history
f CAD. All eligible patients who con-
ented underwent ECG-gated contrast-
nhanced 64-slice multidetector CT. All
atients and caregivers were blinded to the
ndings of the CT. Patients received stan-
ard of care to rule out ACS during index
ospitalization, including serial ECGs,
iomarkers, and cardiac testing (stress test
r cardiac catheterization), as clinically
tilized by the physicians caring for the
atient. The institutional review board
pproved the study protocol, and all patients pro-
ided written informed consent.
For this study, we only included patients who
nderwent clinically indicated rest and stress
ical School, Boston, Massachusetts; and the
as supported by the NIH (R01 HL080053). The
ostics. Drs. Ahmed, Uthamalingam, and Rogers
support from NIH grants K23HL098370 and
stics, Siemens Diagnostics, and BRAHMS. All
ntents of this paper to disclose.
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74SPECT-MPI for risk stratification during index
hospitalization. We excluded patients with myocar-
dial infarction during index hospitalization.
Cardiac biomarker testing. A sample of blood for
iomarker testing (high-sensitivity troponin T
hsTnT]) was taken at the time of computed
omography angiography (CTA), at a median of
.2 h from initial presentation. Blood was immedi-
tely processed and frozen at 80°C, until it was
ssayed with a pre-commercial hsTnT assay (Roche
iagnostics, Penzberg, Germany) on an Elecsys
010 platform (14–16). Given enhanced sensitivity,
he high-sensitivity assay is reported with units of
icograms/milliliter (rather than nanograms/
illiliter for conventional troponin T assays) and is
eported to have a coefficient of variation of 8% at
0 pg/ml (14). For the present analysis, hsTnT had
n inter-run coefficient of variation of 3.6% and
.9% at concentrations of 42 and 2,820 pg/ml,
espectively. All blood was tested on the first
reeze-thaw cycle.
SPECT-MPI. SPECT-MPI using Tc-99m-MIBI
as performed according to American College of
ardiology/American Heart Association image ac-
uisition guidelines using a standard 1-day protocol
17). The median time between hsTnT draw and
TA (which were both performed at the same
ime) and SPECT was 12 h. The patient was first
njected with sestamibi at rest, and ungated images
ere obtained. Subsequently, sestamibi was injected
t peak stress, and gated SPECT images were
btained 30 to 60 min later. Average isotope doses
or sestamibi were in the range of 9 to 11 mCi for
he rest images and 27 to 33 mCi for the stress
mages. Patients performed a treadmill exercise or
ad pharmacological stress testing with adenosine if
nable to exercise. Beta-blockers were held before
tress testing for all patients. Patients were in-
tructed not to consume coffee or other products
ontaining caffeine for 24 h before the test. During
oth types of stress testing, heart rate, blood pres-
ure, and 12-lead ECG were recorded at baseline
nd every minute thereafter, and as needed appropri-
tely. One minute before completion of symptom-
imited exercise (test endpoint as defined in the
urrent practice guideline [18]), radiotracer was
njected intravenously. A dual-head Siemens
amma camera (E-CAM or C-CAM, Siemens
edical Solutions, Forchheim, Germany) equipped
ith a low-energy, high-resolution collimator (32
iews per camera head in 64  64 matrix) was used
or image acquisition.The nuclear images were analyzed separately by 2
ndependent readers who were blinded to the clin-
cal history, the CTA results, and the patient’s
utcome. Readers were also blinded to each other’s
eadings. Discrepancies were adjudicated by a third
eader. Analysis was done in a semiquantitative
ashion using a standard 17-segment model and a
-point scoring system (19) using commercially
vailable SPECT image analysis program (4DM,
nn Arbor, Michigan). Analysis was performed
linded to the results of CTA and cardiac biomark-
rs. Global summed scores were computed for the
tress images (summed stress score [SSS], reflecting
he combined extent and severity of ischemia plus
car) and rest images (summed rest score [SRS],
eflecting the extent and severity of myocardial
car), as well as their difference (summed difference
core [SDS], reflecting the combined extent and
agnitude of myocardial ischemia). An MPI result
as considered to be abnormal if the SSS was 4
nd/or the SDS 1 (primary endpoint) (20,21).
ransient ischemic dilation (TID) was estimated
rom the semiautomated analysis of the ratio of the
eft ventricle volume on rest and stress MPI images.
CTA. CT imaging was performed using a standard
4-slice multidetector CT coronary angiography
canner (Sensation 64, Siemens Medical Solutions)
rotocol that was acquired at end-inspiration and
ncluded the administration of sublingual nitroglyc-
rin (0.6 mg) and intravenous beta-blocker (meto-
rolol 5 to 20 mg) for those with a baseline heart
ate 60 beats/min and no other contraindications.
test bolus protocol was used to determine the
ptimal timing of contrast injection (20 ml of
ontrast agent followed by 40 ml of saline, flow rate
f 5 ml/s). Contrast agent (80 to 100 ml, Iodixanol
20 g/cm3, Visipaque, GE Healthcare, Princeton,
ew Jersey) with 40 ml of saline was injected
ntravenously at a rate of 5 ml/s. CT images were
cquired in spiral mode, gantry rotation time of 330
s, 64  0.6-mm slice collimation, tube voltage of
120 kV, effective tube current of 850 to 950 mAs,
with ECG-correlated tube current modulation
when appropriate. For coronary artery assessment,
axial images were reconstructed using a medium-
sharp convolution kernel with a slice thickness of
0.75 mm and increment of 0.4 mm.
For the detection of CAD, the 17-segment
model based on the American Heart Association
classification with the addition of the posterior left
ventricular branch as segment 16 and the ramus
intermedius as segment 17 was used (22). For each
of the 17 segments, coronary atherosclerotic plaque,
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75plaque composition (calcified, mixed, or noncalci-
fied), and significant stenosis (defined as luminal
narrowing50% diameter) was visually classified as
either present or absent as previously described and
determined by 2-reader consensus using a Leonardo
workstation (Siemens Medical Solutions) as previ-
ously validated (23). The extent of coronary plaque
burden was scored from 0 to 17 and treated as a
continuous variable.
Statistical analysis. Baseline demographics of pa-
tients with normal and abnormal stress tests were
compared with the Fisher exact test for categorical
variables and 1-way analysis of variance or Kruskal-
Wallis test for continuous variables. For pairwise
comparisons, the Student t test or Wilcoxon rank
sum test was used.
The Wilcoxon rank sum test was used to deter-
mine the significance of differences in hsTnT levels
between normal and abnormal SPECT-MPI pa-
tients. The probability of having an abnormal stress
test at different hsTnT levels was calculated using
unadjusted logistic regression. In order to deter-
mine cutoff values of hsTnT representing different
sensitivities (60%, 70%, 80%, 90%) for abnormal
SPECT-MPI, receiver-operating characteristic curves
were constructed, and the area under the curve
(AUC) (24) was estimated. Specificity, positive
predictive value (PPV) and negative predictive value
(NPV) including 95% confidence intervals [CI] for
an abnormal SPECT-MPI were determined for
each level of sensitivity. The C-statistic values,
which are equal to the AUC for each level of
sensitivity, were calculated. Following the intention-
to-treat principle, the number of true negative stress
tests that could be saved for each false negative test
(hsTnT below the cutoff, but with an abnormal
SPECT-MPI) was calculated for each level of
sensitivity.
Log-transformed hsTnT levels were normally
distributed and were used to assess associations
between hsTnT and SPECT-MPI, coronary CTA,
and cardiovascular risk factors. Univariate linear
regression analysis was performed, and parameters
with p  0.1 were included in multivariate analysis.
he baseline model (Model 1) adjusted the associ-
tion of hsTnT and cardiac stress testing for age
nd sex (strong association of these with hsTnT in
rior studies) (6). In a second model, we further
djusted for other traditional CAD risk factors.
The association of reversible myocardial ischemia
SDS) and atherosclerotic plaque burden (number
f coronary segments with any plaque) with hsTnT
as assessed independently using linear regression 7nalysis. Adjusted and partial r-squares were calcu-
ated to determine the extent to which variation of
og-transformed hsTnT levels could be explained by
eversible ischemia and plaque burden. Any increase
n adjusted r-square was interpreted as incremental
mprovement in the model.
All of the statistical analyses were performed with
AS software (version 9.2, SAS Institute, Cary,
orth Carolina). All probability values were
-sided, with a level of significance of 0.05.
R E S U L T S
Study population. We included 138 patients with
cute chest pain (mean age 54  11 years, 46%
ale) who underwent clinically indicated exercise
readmill testing SPECT-MPI (n  99) or aden-
sine SPECT-MPI (n  39) for risk stratification
uring index hospitalization. In 7 patients, hsTnT
alues were missing, including in 1 patient with
bnormal myocardial perfusion by SPECT-MPI.
sTnT levels, measured on average 4 h after
resentation, were low (median: 5.43 pg/ml [inter-
uartile range (IQR): 2.42 to 8.71 pg/ml], range: 0
o 42.4 pg/ml). The majority (86%) had values
elow the 99th percentile of hsTnT for a normal
eference population (13 pg/ml).
HsTnT and SPECT-MPI. Overall, 19 (13.7%) patients
ad abnormal SPECT-MPI, among them 10 pa-
ients with SDS 1 and 9 with SSS 4. Seven of
he 10 patients with SDS 1 also had SSS 4.
ean SSS, SRS, and SDS were 1.23  4.46,
.82  3.21, and 0.41  1.81, respectively. Mean
eft ventricular ejection fraction was 65.5  11.4%
nd mean TID was 0.97  0.16. Seven of the 19
atients (5 with abnormal SDS and 2 with only
bnormal SSS) also had significant stenosis on
TA or invasive angiography (if available). The
tenosis location correlated with the location of the
erfusion defect in all 7 patients. There were no
ifferences in cardiovascular risk profile, medication
se, and extent of plaque by CTA between patients
ith normal (n 119, 86%) and abnormal (n 19,
4%) SPECT-MPI (Table 1). However, signifi-
antly more patients with abnormal SPECT-MPI
ad significant coronary stenosis than those with a
ormal SPECT-MPI (p  0.003).
Median hsTnT levels were twice as high in
atients with abnormal SPECT-MPI compared
ith those with normal SPECT-MPI (9.41 pg/ml
IQR: 5.73 to 19.20] vs. 4.89 pg/ml [IQR: 2.34 to
.68], p  0.001) (Fig. 1). This difference was
hlysis
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76independent of age and sex and other traditional
cardiovascular risk factors (p  0.02).
The probability of having an abnormal SPECT-
MPI increased from 9% (95% CI: 5% to 16%) at a
hsTnT value of 3 pg/ml, to 13% (95% CI: 8% to
21%) for a hsTnT value of 10 pg/ml, and to 21%
(95% CI: 13% to 33%) for a hsTnT level of 20
pg/ml. The odds for abnormal SPECT-MPI in-
creased by 2-fold per doubling of hsTnT levels
(odds ratio: 2.19 [95% CI: 1.41 to 3.39], p 0.002).
Consequently, hsTnT had good discriminatory value
for abnormal SPECT-MPI (AUC: 0.739, 95% CI:
0.609 to 0.868) (Fig. 2).
The odds for abnormal SPECT-MPI increased
4-fold per doubling of hsTnT levels (odds ratio:
4.40 [95% CI: 1.93 to 10.00], p  0.0004) among
patients with abnormal SPECT-MPI who also had
significant stenosis.
To provide clinically relevant thresholds, we de-
termined the specificity, PPV, and NPV of hsTnT
Table 1. Baseline Characteristics of the Study Population
Characteristic
Overall Cohort
(N  138)
Age, yrs 54 11
Male 63 (46)
Cardiovascular risk factors
Body mass index, kg/m2 30 6
Diabetes mellitus 16 (12)
Hypertension 56 (41)
Hyperlipidemia 59 (43)
Family history of CAD 36 (26)
Tobacco use 40 (29)
Medications at presentation
Aspirin 44 (32)
Statin 46 (33)
Nitroglycerin 4 (3)
Beta-blocker 32 (23)
TIMI score
0 Points 63 (46%)
1 Point 50 (36%)
2 Points 19 (14%)
3 Points 6 (4%)
Coronary CTA
Presence of any plaque 72 (52)
Segments with any plaque 1 [0–3]
Presence of signiﬁcant stenosis 13 (9)
Biomarkers (other than hsTnT)
hsCRP, pg/ml 1.44 [0.71–2.98]
NT-proBNP, pg/ml 41 [21–100]
Values are mean  SD, median [interquartile range], or n (%). *p value for differ
adenosine single-photon emission computed tomography-myocardial perfusio
CAD  coronary artery disease; CTA  computed tomography angiography
NT-proBNP  amino-terminal pro–B-type natriuretic peptide; TIMI  Thrombofor SPECT-MPI testing results at predefined levels aof sensitivity of 60%, 70%, 80%, and 90%, as well as
the diagnostic accuracy of hsTnT at values corre-
sponding to the 99th percentile of a healthy refer-
ence population (13 pg/ml) (6) (Table 2). High
sensitivities of 80% and 90% for abnormal SPECT-
MPI still rendered reasonable specificities of 62%
and 46%, respectively, but most importantly, re-
sulted in a consistently high NPV of 96%. Remark-
ably, the 99th percentile of a healthy reference
population (13 pg/ml) rendered excellent specificity
and NPV (96% each) but poor sensitivity (26%).
Translating these numbers according to the
intention-to-treat principle, 27.0, 18.5, 15.6, and
13.6 true negative SPECT-MPI tests could be
saved at sensitivities of 60%, 70%, 80%, and 90%,
respectively, for a penalty of 1 false negative test
(abnormal SPECT-MPI).
Myocardial ischemia and coronary atherosclerosis in-
dependently predict hsTnT. To assess whether
sTnT is a marker of both upstream (coronary
mal SPECT-MPI
(n  119)
Abnormal SPECT-MPI
(n  19) p Value*
53 11 56 12 0.26
58 (49) 5 (26) 0.08
30 6 30 6 0.85
11 (9) 5 (26) 0.05
50 (42) 6 (32) 0.46
51 (43) 8 (42) 1.00
33 (28) 3 (16) 0.40
33 (28) 7 (37) 0.42
38 (32) 6 (32) 1.00
40 (34) 6 (32) 1.00
3 (3) 1 (5) 0.45
31 (26) 1 (5) 0.07
0.12†
57 (48%) 6 (32%)
43 (36%) 7 (37%)
14 (11%) 5 (26%)
5 (4%) 1 (5%)
61 (51) 11 (58) 0.63
1 [0–3] 1 [0–7] 0.21
7 (6) 6 (32) 0.003
42 [0.69–2.93] 1.66 [1.82–3.34] 0.85
40 [20–102] 52 [32–100] 0.25
s between normal and abnormal stress testing (includes exercise treadmill and
ging (SPECT-MPI). †Mantel-Haenszel trend test.
RP  high-sensitivity C-reactive protein; hsTnT  high-sensitivity troponin T;
In Myocardial Infarction.Nor
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77emia) aspects of cardiovascular disease, we deter-
mined whether both are associated with elevated
hsTnT levels. In univariate analysis, SSS, SRS, and
SDS, as well as left ventricular ejection fraction and
TID ratio, were significantly associated with hsTnT
(  0.07, 0.08, and 0.19; 0.02 and 1.24, respec-
ively, all p  0.01) (Table 3). In adjusted analysis,
SS, SRS, and SDS remained significant predictors
f hsTnT ( 0.06, 0.07, and 0.16, respectively, all
p  0.005).
Among a total of 2,346 CTA segments from 138
patients assessed for plaque burden, 78 segments
(3.3%) were considered indeterminate. In separate
linear regression models, both the extent of revers-
ible myocardial ischemia (SDS) and extent of cor-
onary atherosclerosis were associated with hsTnT
(SDS r2  0.15, p  0.0001; plaque r2  0.08, p 
0.0004) (Fig. 3). Combined information on myo-
cardial ischemia and coronary atherosclerosis ex-
plained nearly 20% of the variability in hsTnT, and
the 2 variables were independent of each other
(combined model r2  0.19 with partial r2  0.12
hs
Tn
T 
(p
g/m
L)
Abnormal
SPECT-MPI
Normal
SPECT-MPI
0
10
20
30
40
50
60
70
80
Figure 1. HsTnT Levels Between Patients With Normal and
Abnormal SPECT-MPI
Median high-sensitivity troponin T (hsTnT) levels were signiﬁ-
cantly higher in patients with abnormal single-photon emission
computed tomography–myocardial perfusion imaging (SPECT-
MPI) compared with those with normal SPECT-MPI (9.41 pg/ml
[interquartile range (IQR): 5.73 to 19.20 pg/ml] vs. 4.89 pg/ml
[IQR: 2.34 to 7.68 pg/ml], p  0.001).for SDS and partial r2  0.05 for plaque) (Fig. 4).Notably, addition of significant coronary disease
(50% stenosis on CTA) to the model did not
result in improvement (model r2 0.18). However,
analysis stratified by plaque composition suggested
that mixed plaque was significantly associated with
hsTnT levels (  0.17, p  0.02), whereas
noncalcified (  0.015, p  0.87) and calcified
(  0.07, p  0.06) plaque were not.
Furthermore, hsTnT levels in those with abnor-
al SPECT-MPI increased with the presence and
everity of CAD: patients with abnormal SPECT-
PI and matching stenosis on CTA (n  7, 30.5
g/ml [IQR: 8.62 to 61.3]), patients with abnormal
PECT-MPI and matching stenosis who were
evascularized (n  4, 60.9 pg/ml [IQR: 36.1 to 65
g/ml]), and patients with abnormal SPECT-MPI,
ut without significant CAD (n  12, 8.00 pg/ml
IQR: 5.4 to 12.4 pg/ml]) as compared with those
ith normal SPECT-MPI (4.89 pg/ml [IQR: 2.34
o 7.68 pg/ml]), all p  0.03.
D I S C U S S I O N
In this substudy of ROMICAT I, we assessed the
diagnostic accuracy of a single hsTnT measurement
for the detection of abnormal rest stress SPECT-
MPI and CAD in patients presenting to the ED
with acute chest discomfort, but without objective
evidence for ACS. We found that hsTnT levels
measured on average 4 h after ED presentation
were significantly higher in abnormal as compared
with normal SPECT-MPI patients, independent of
age, sex, and other cardiovascular risk factors. Most
importantly, hsTnT had excellent NPV (96%) for
normal SPECT-MPI while maintaining reasonable
PPV and specificity. The discriminatory value of
hsTnT was very good (AUC: 0.768). For example,
at a sensitivity level of 90%, hsTnT correctly pre-
dicted 16 normal SPECT-MPI at a penalty of 1
abnormal SPECT-MPI. These results are sup-
ported by subanalyses demonstrating the indepen-
dent association of hsTnT with both reversible
myocardial ischemia and the extent of CAD. More-
over, whereas hsTnT levels were significantly
higher in patients with abnormal SPECT-MPI
compared with normal SPECT-MPI patients, the
level of hsTnT in those with abnormal SPECT-
MPI increased with the presence and severity of
CAD. The fact that mixed plaque was associated
with high hsTnT levels suggests that hsTnT may be
a predictor of culprit lesions for unstable angina
pectoris. Overall, these data suggest that early
resting hsTnT could serve as a powerful triage tool
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78in chest pain patients in the ED before diagnostic
testing and thus could improve the effectiveness of
patient management.
HsTnT for management of acute chest pain patients.
The major finding of this double-blinded cross-
sectional cohort study is that resting hsTnT levels
drawn about 4 h after ED presentation, but about
12 h before stress testing, predict abnormal myo-
cardial perfusion independent of cardiovascular risk
factors or time of presentation to ED after onset of
Table 2. Utility of Various HsTnT Cutoff Values for Identifying C
Cut Points for
HsTnT (pg/ml)
Target sensitivity
60% 8.62
70% 6.31
80% 5.73
90% 4.26
99th percentile of a reference group (6) 13.00
CI conﬁdence interval; hsTnT high-sensitivity troponin T; NPV negative pr
8.62 pg/mL
6.31 pg/mL
5.73 pg/mL
4.26
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Figure 2. ROC Curve for hsTnT Values for Prediction of Abnorm
HsTnT had good discriminatory value for abnormal SPECT-MPI (area
0.868). The hsTnT cutoffs for sensitivities of 60%, 70%, 80%, and 90
Other abbreviations as in Figure 1.computed tomography–myocardial perfusion imaging.symptoms. The predictive ability occurs at very low
levels of hsTnT (9.41 pg/ml vs. 4.89 pg/ml, p 
0.001 for normal vs. abnormal SPECT-MPI), well
below detection levels of conventional TnT and the
99th percentile of hsTnT in a healthy reference
population (6). Excellent discriminatory power
(AUC: 0.739, 95% CI: 0.609 to 0.868) was main-
tained at hsTnT values between 4 and 8 pg/ml,
corresponding to sensitivities of 60% to 90%. Most
importantly, hsTnT rendered an excellent NPV of
t Pain Patients With Abnormal SPECT-MPI Results
nsitivity
5% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
(35–83) 78% (69–85) 31% (16–48) 93% (85–97)
(47–90) 65% (55–73) 25% (14–38) 94% (86–98)
(52–94) 62% (52–71) 25% (14–38) 95% (87–97)
(65–99) 46% (37–56) 21% (12–32) 96% (87–100)
(10–53) 98% (81–94) 28% (10–53) 88% (81–94)
ive value; PPV positive predictive value; SPECT-MPI single-photon emission
/mL
hsTnT
AUC: 0.739 (95%CI: 0.609 - 0.868) 
ecificity
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7996% while maintaining fair specificity and PPV
(i.e., 90% sensitivity, 46% specificity, 21% PPV).
This means that hsTnT can be utilized to predict
abnormal SPECT results.
Overall, our findings suggest that early resting
hsTnT may improve the effectiveness of the man-
agement of patients with acute chest pain and
low-to-intermediate risk for ACS. Given the low
prevalence of abnormal SPECT-MPI and ACS in
this population and the risks and costs associated
with diagnostic testing, early hsTnT testing may
eliminate the need for imaging in a substantial
number of patients who currently undergo 1 or
more diagnostic imaging tests. If confirmed in
prospective evaluations, a substantial fraction of
patients with acute chest pain may be eligible for
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Figure 3. Correlation of HsTnT With Extent of Reversible Myoca
The levels of log-transformed high-sensitivity troponin T (hsTnT) we
cles), a measure of reversible myocardial ischemia, and to coronary
2
Table 3. SPECT-MPI Stress Test Parameters as Predictors of Log
SPECT-MPI (Both Exercis
Univariate
SPECT Parameters  p Value
SSS 0.07 0.0001
SRS 0.08 0.0008
SDS 0.19 0.0001
LVEF by gated SPECT 0.02 0.003
TID ratio 1.24 0.01
Model 1 was adjusted for age and sex; Model 2 for age, sex, diabetes, and hyp
LVEF  left ventricular ejection fraction; SDS  summed difference score; SRS 
other abbreviations as in Table 2.erosclerotic plaque burden. The correlation coefﬁcients were r  0.15immediate and safe discharge by utilizing a strategy
involving hsTnT for risk stratification.
HsTnT, myocardial ischemia, and CAD. Recently pub-
ished data suggest that hsTnT is a marker for
ardiac structure and function (12) and potentially
ulnerable coronary atherosclerotic plaque (24).
hus, in this study, we hypothesized that very low
evels of hsTnT, well below established cutoffs for
yocardial infarction, can serve as a composite
arker of both reversible myocardial ischemia and
xtent and composition of CAD. Our findings
upport this hypothesis, as both the presence of
ixed plaque and reversible ischemia were signifi-
antly and independently associated with hsTnT
evels. This could provide a mechanistic explanation
or previous observations demonstrating that mixed
r2=0.08
r2=0.15
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l Ischemia as Well as With Coronary Atherosclerotic Plaque
orrelated separately to summed difference score (SDS) (red cir-
ments containing any plaque (blue squares), a measure of ath-
2
nsformed HsTnT Concentrations
d Adenosine, N  138)
Multivariate (Model 1) Multivariate (Model 2)
 p Value  p Value
0.07 0.0001 0.06 0.0002
0.07 0.001 0.07 0.005
0.17 0.0001 0.16 0.0001
0.02 0.004 0.02 0.01
1.04 0.02 0.84 0.07
nsion.
med rest score; SSS  summed stress score; TID  transient ischemic dilation;ed
rdia
re c
seg-Tra
e an
erte
sum(p  0.0001) and r  0.08 (p  0.0004), respectively.
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80plaque is the primary driver of the association of
plaque burden with cardiovascular events (25,26).
Taken together with other studies, our data
generate the hypothesis that increased hsTnT
Figure 4. Association of Estimated HsTnT Levels With Reversibl
The levels of log-transformed high-sensitivity troponin T (hsTnT) we
reversible myocardial ischemia (summed difference score [SDS]) and
rotic plaque as predictors. For better clinical interpretation, the labe
hsTnT levels with a unit of picograms/milliliter. Combined informati
nearly 20% of the variability in hsTnT (r2  0.19), and the 2 variable
illustrated by different colors as shown in the color key.
Figure 5. Various Pathophysiological Mechanisms for the ReleaCAD  coronary artery disease; HsTnT  high-sensitivity troponin T.may be a result of provocable ischemia both in the
presence and absence of significant coronary dis-
ease, potentially via plaque rupture with distal
embolization (Fig. 5).
yocardial Ischemia and Coronary Plaque Extent
stimated with a linear regression model using the extent of
e number of coronary artery segments containing any atheroscle-
of the y-axis was back-transformed from log-hsTnT levels into
n myocardial ischemia and coronary atherosclerosis explained
ere independent of each other. The estimated levels of hsTnT are
f HsTnT in the Circulatione M
re e
th
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on o
s wse o
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81The source and nature for detectable hsTnT
levels remain debated, but there is agreement that
they do not represent the traditional level of myo-
cardial necrosis seen as a result of thrombotic
occlusion (27). More likely, very low levels of
circulating troponin may represent myocyte stress
or damage (28), possibly as a result of changes in
cell membrane permeability (29). Stress-induced
myocardial ischemia leading to a quantifiable rise in
high-sensitivity troponin I has been recently dem-
onstrated in patients with stable angina (11). Our
findings extend this observation because we dem-
onstrate a strong association of resting pre-stress
hsTnT levels with reversible myocardial ischemia in
acute chest pain patients.
Furthermore, hsTnT may constitute, not only an
attractive diagnostic and prognostic marker in pa-
tients with acute chest pain presenting to the ED,
but also a potential therapeutic target for pharma-
cological interventions in primary and secondary
prevention strategies.
Study limitations. In this study, hsTnT testing was
performed contemporaneously with the CT scan
and on average 4 h after ED presentation and 12 h
before cardiac stress testing. Thus, the value of
earlier or serial hsTnT for risk stratification as
suggested previously (30,31) could not be estab-
lished. In addition, a pre-commercial hsTnT assay
was used that permitted detection of lower hsTnT
levels than a commercially available assay. However,
the reproducibility of low hsTnT concentrations99th percentile reference cutoffs for and the predictedthe overall population of patients presenting with
acute chest pain to the ED, because this was a
single-center study with enrollment limited to
weekday daytime hours that excluded patients with
prior CAD and enrolled very few elderly patients.
Our study was a cross-sectional observational study
and thus is limited to generating a hypothesis.
C O N C L U S I O N S
In acute chest pain patients undergoing SPECT
imaging for risk assessment, myocardial perfusion
abnormalities, as well as the extent of CAD, are
predicted by resting hsTnT levels. If confirmed in
prospective evaluations, resting hsTnT could serve
as a powerful triage tool in chest pain patients in the
ED before diagnostic testing and thus could im-
prove the effectiveness of patient management by
eliminating the need for imaging in a substantial
number of these patients.
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